Dendreon Corp . ( DNDN ) Cowen and Company 34th Annual Health ..... by John Johnson, Chairman and CEO of Dendreon and looking forward to his updates ..... I may make today. So if you look at Dendreon , yesterday we announced our fourth
break time for biotech Dendreon ( DNDN ). The company that ..... prostate cancer treatment Provenge had an upcoming earnings ..... including the launch of Provenge in Europe. Unfortunately ..... transparency was not good. Dendreon has a tremendous opportunity ..... better. Q4 results: Dendreon did pre-announce results
Start Time: 09:00 End Time: 10:00 Dendreon Corporation ( DNDN ) Q4 2013 Earnings Conference Call March 03, 2014 ..... Good morning, ladies and gentlemen, and welcome to Dendreon 's Fourth Quarter and Year End 2013 Earnings Conference
Dendreon reported fourth-quarter results ..... expectations. The stabilization of Provenge revenue and the announcement of the ..... estimate and our no-moat rating. Dendreon reported $74.8 million in Provenge sales for the quarter, up 10
Dendreon ( DNDN ) jumps 20% after the company ..... company says it plans to sell Provenge in Europe, beginning with ..... approval in September. Dendreon will initially look to sell ..... company will consider making Provenge more widely available
(Reuters) - Biotechnology company Dendreon Corp said it would start selling its prostate cancer vaccine Provenge in Europe, sending its shares up nearly 15 percent in premarket trading.
Complete Story »
Dendreon Corporation ( DNDN ): Q4 EPS of -$0.17 beats by $0.07. Revenue of $74.83M (-12.5% Y/Y) beats by $1.24M . Press Release Post your comment!
quarter than for biotech darling Dendreon ( DNDN ). The name that brings you the prostate cancer treatment Provenge has a lot to prove in 2014 ..... investors need to prepare. Dendreon has a number of questions ..... 2013: About a month ago, Dendreon pre-announced some of its
investment option, both short and long-term. The Current State of Cancer Therapeutics In the early 2000s it was Dendreon 's ( DNDN ) Provenge that was apparently steps above other cancer therapeutics in development. But turns out it was a drug from